CVRx Inc. reported its financial and operating results for the fourth quarter (Q4) and full year (FY) 2025. Total revenue for Q4 2025 was USD 16.0 million, reflecting a 4% increase. U.S. revenue for the quarter reached USD 14.9 million, also up 4%. For FY 2025, total revenue amounted to USD 56.7 million, an increase of 10%. The company reported a net loss per share, basic and diluted, of USD 0.46 for Q4 2025. Cash and cash equivalents as of December 31, 2025, totaled USD 75.71 million. Operational highlights for the period include growth in the number of active implanting centers in the U.S. to 252, up from 223 in the prior year. CVRx also initiated the BENEFIT-HF trial, with first enrollments expected in the second quarter of 2026. Looking ahead, CVRx expects full year 2026 total revenue to be between USD 63.0 million and USD 67.0 million, gross margin between 84% and 86%, and operating expenses between USD 103.0 million and USD 107.0 million. For the first quarter (Q1) of 2026, the company anticipates total revenue between USD 13.7 million and USD 14.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9653213) on February 12, 2026, and is solely responsible for the information contained therein.